Australia's most trusted
source of pharma news
Posted 21 August 2025 AM
After winning reimbursement just last year Pfizer's heart drug Vyndamax has taken off, recording the second highest growth in dollar terms on the PBS in the first half of 2025, beaten only by MSD's oncology juggernaut, Keytruda.
The transthyretin stabiliser was listed in May 2024 for adults with wild-type or hereditary transthyretin amyloid cardiomyopathy with NYHA Class I-II heart failure. It earned Pfizer $84 million more between January and June, than the same period last year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.